Use of Bone Marrow Biopsies in Patients With Chronic Immune Thrombocytopenia: Predictors For, And Prognosis After – a Nordic Population-based Cohort Study And a Nested Case Control Study

Study identification

• EU PAS number:
  EUPAS33657
• Study ID:
  39431
• Official title and acronym:
  Use of Bone Marrow Biopsies in Patients With Chronic Immune Thrombocytopenia: Predictors For, And Prognosis After – a Nordic Population-based Cohort Study And a Nested Case Control Study
• DARWIN EU® study:
  No
• Study countries:
  Denmark

  Norway

  Sweden
• Study description:
  The study will characterize patients with chronic immune thrombocytopenia, including prevalence and incidence of biopsies, risk factors associated with biopsies, and outcomes among these patients.
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Aarhus University & Aarhus University Hospital CLINICAL EPIDEMIOLOGY AND DATA SCIENCE, DEPARTMENT OF CLINICAL MEDICINE

Denmark

Centre for Pharmacoepidemiology, Karolinska Institutet (CPE-KI)

Sweden

Study timelines

Date when funding contract was signed

Planned:12/09/2019

Actual:12/09/2019

Study start date

Planned:25/02/2020

Actual:25/02/2020

Data analysis start date

Planned:26/02/2020

Actual:26/02/2020

Date of final study report

Planned:30/07/2020

Actual:08/02/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen, Ltd

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable